Amgen Inc (LTS:0R0T)
$ 269.5 0 (0%) Market Cap: 174.85 Bil Enterprise Value: 226.24 Bil PE Ratio: 41.65 PB Ratio: 23.23 GF Score: 91/100

Amgen Inc M&A Call on Five Prime Therapeutics Inc Acquisition Transcript

Mar 04, 2021 / 03:30PM GMT
Release Date Price: $226.98 (+1.29%)
Operator

Good day, ladies and gentlemen. My name is Carmen, and I will be your conference facilitator for today, Amgen's conference call on the Five Prime acquisition. (Operator Instructions) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may begin.

Arvind Sood
Amgen Inc. - VP of IR

Okay, Carmen. Thank you. And good morning, everybody. Thank you for joining us on such short notice. We wanted to tell you about an exciting development, our acquisition of Five Prime therapeutics. This is a company that's focused on developing immuno-oncology and targeted cancer therapies. We are looking forward to discussing Five Prime's lead product in development, bemarituzumab, that, by the way, we'll affectionately call bema going forward. Bema is a novel antifibroblast growth factor receptor antibody which is being developed initially for gastric cancer.

I am joined this morning by our CFO, Peter Griffith, who will discuss the strategic rationale and complementarity of this asset within oncology, which, as you know, is one of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot